典型文献
Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction
文献摘要：
Objective:To evaluate the effect and safety of low-dose of apatinib and S-1 combined with Jianpi Bushen Jiedu Decoction(JBJD)in patients with metastatic colorectal cancer(mCRC)who have failed second or above lines treatment,in order to provide more treatment option for mCRC patients by integrated medicine.Methods:Thirteen patients were selected from a single-arm,open-label clinical study from April 2019 to September 2020.The patients were treated with low-dose apatinib(250 mg,once a day)and S-1(20 mg,twice a day)combined with JBJD for at least one cycle and were followed up to August 2021.The primary endpoint was disease progression-free survival(PFS).Disease control rate(DCR),objective response rate(ORR),and overall survival(OS)of patients were observed as the secondary endpoints.Adverse events were recorded as well.Results:The average age of the 13 patients was 56.5±13.0 years and 76.9％were male.The median PFS and median OS were 4.6 and 8.3 months,respectively.The ORR was 7.7％(1/13)while the DCR was 61.5％(8/13).The common adverse events were hypertension,proteinuria,elevated transaminase,and thrombocytopenia.One patient experienced thrombocytopenia of grade 3.Conclusions:Patients with mCRC after failure of the second or above lines of treatment may potentially benefit from the treatment of low-dose apatinib and S-1 combined with JBJD because of its similar effect as the standard dose of target therapy and relatively better safety.(Registration No.ChiCTR1900022673)
文献关键词：
中图分类号：
作者姓名：
CHEN Yue;XU Yu-ying;JIANG Hai-jun;WANG Lei;ZHAI Jia-wei;ZHANG Tong;YANG Yu-fei
作者机构：
Graduate School,Beijing University of Chinese Medicine,Beijing 100029,China;Department of Oncology,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;Department of Oncology,Central Hospital of Ankang City,Ankang,Shaanxi Province 725000,China
文献出处：
引用格式：
[1]CHEN Yue;XU Yu-ying;JIANG Hai-jun;WANG Lei;ZHAI Jia-wei;ZHANG Tong;YANG Yu-fei-.Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction)[J].中国结合医学杂志（英文版）,2022(10):924-929
A类：
Bushen,JBJD,ChiCTR1900022673
B类：
Patients,Metastatic,Colorectal,Cancer,after,Failure,Second,Line,Treatment,May,Benefit,from,Low,Dose,Apatinib,Combined,Jianpi,Jiedu,Decoction,Objective,To,evaluate,effect,safety,dose,apatinib,combined,patients,metastatic,colorectal,cancer,mCRC,who,have,failed,above,lines,treatment,order,provide,more,option,by,integrated,medicine,Methods,Thirteen,were,selected,single,arm,label,clinical,study,April,September,treated,once,day,twice,least,one,cycle,followed,up,August,primary,was,disease,progression,free,survival,PFS,Disease,control,DCR,objective,response,ORR,overall,OS,observed,secondary,endpoints,Adverse,events,recorded,well,Results,average,years,male,median,months,respectively,while,common,adverse,hypertension,proteinuria,elevated,transaminase,thrombocytopenia,One,experienced,grade,Conclusions,failure,may,potentially,benefit,because,its,similar,standard,target,therapy,relatively,better,Registration,No
AB值：
0.557172
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
